Latest Content

After a lung cancer diagnosis, one Bronx writer reflects on faith, survivorship and learning that healing isn't a finish line, but a daily journey.

Dr. David DiBardino explains how intratumoral therapy is being studied to deliver treatment directly into tumors and potentially enhance radiation in patients with locally advanced non-small cell lung cancer.

After lymphoma returned in his brain, one cancer survivor reflects on hospice, mortality, family, jealousy and gratitude for the life he was able to live.

See how FDA-approved lymphoma treatments have changed over 5 years — what's new, who it's helped, and what's still to come.

Kazia Therapeutics CEO Dr. John Friend discussed how paxalisib is being studied in HR-positive, HER2-negative breast cancer, why researchers are focusing on treatment resistance and what the ongoing clinical trial could show for patients.

An expert discusses August's FDA approvals for myeloma, polycythemia vera and essential thrombocythemia, plus first-line myeloma care and MRD testing.

Patients with colorectal cancer who walked more had less fatigue and better quality of life, regardless of how active they were at diagnosis.

CURE spoke with Oncology Aesthetics & Wellness founder, Deborah A. McDowell, about hair preservation before, during and after cancer treatment.

A genomic test led physicians to change extended endocrine therapy recommendations for 42% of people with early-stage HR-positive breast cancer.

Survivors and experts share what to do before your first chemo infusion, from scalp cooling and saving your hair to skin care and building a support team.

After two relapses of acute lymphoblastic leukemia, Hannah Koepsell received CAR-T cell therapy. A pediatric oncologist explains why leukemia can return after treatment and how researchers are working to make CAR-T responses last longer.

FDA approves Welireg plus Lenvima for advanced clear cell kidney cancer after PD-1 or PD-L1 treatment, offering a new treatment option.

These seven breast cancer clinical trials are recruiting patients now, spanning early-stage, HR-positive, HER2-positive and triple-negative disease.